Pacira (PCRX) Gets European Commission Approval for Exparel
The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.
Zacks · 11/19 15:08
Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU
Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.
Zacks · 11/16 15:06
Microcaps mostly among midday movers
Gainers: Urovant Sciences Ltd. (UROV) +94%.CBAK Energy Technology, Inc. (CBAT) +68%.Asia Pacific Wire & Cable Corporation Limited (APWC) +63%.National Holdings Corporation (NHLD) +46%.Electrameccanica Vehicles Corp. (SOLO) +35%.Polar Power, Inc. (POLA)
Seekingalpha · 11/13 18:15
Mid-Day Market Update: Gold Rises 1%; Cassava Sciences Shares Plunge
Midway through trading Friday, the Dow traded up 0.81% to 29,315.09 while the NASDAQ rose 0.34% to 11,749.17. The S&P also rose, gaining 0.69% to 3,561.36.
Benzinga · 11/13 17:02
Why Cassava Sciences Stock Is Trading Lower Today
Cassava Sciences (NASDAQ: SAVA) shares are trading lower on Friday after the company announced a common stock offering. No size was disclosed.
Benzinga · 11/13 16:24
Urovant Sciences, Zomedica leads healthcare gainers; Cassava Sciences, Allied Healthcare Products among major losers
Gainers: Urovant Sciences (UROV) +94%, Zomedica (ZOM) +35%, Ovid Therapeutics (OVID) +16%, Fulgent Genetics (FLGT) +12%, Myovant Sciences (MYOV) +11%.Losers: Cassava Sciences (SAVA) -26%, Allied Healthcare Products (AHPI) -24%, Biocept (BIOC) -19%, Zhongchao (ZCMD) -14%, IMAC Holdings (IMAC) -14%.
Seekingalpha · 11/13 16:03
Zoetis (ZTS) Librela Gets Marketing Authorization in Europe
Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.
Zacks · 11/13 14:42
Cassava Sciences prices $75M equity offering
Cassava Sciences (SAVA) prices public offering of 9,375,000 shares of its common stock at $0.001/share.Gross proceeds will be ~$75M, excluding the exercise of underwriter’s option to purchase up to an additional
Seekingalpha · 11/13 14:29
Cassava Sciences Announces Pricing Of $75M Offering At $8/Share
Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) (the "Company" or "Cassava
Benzinga · 11/13 14:09
Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock
GlobeNewswire · 11/13 14:08
American Well, BigCommerce Holdings leads premarket losers' pack
Cassava Sciences (SAVA) -18% after announcing proposed public offering.Shift Technologies (SFT) -18% on Q3 earnings release.IMAC Holdings (IMAC) -17%.EuroDry (EDRY) -15%.Biocept (BIOC) -15% on Q3 earnings release.Creative Realities (CREX) -12% on Q3 earnings release.Zhongchao (ZCMD) -12%.Allied Healthcare Products
Seekingalpha · 11/13 13:26
Cassava Sciences plunges after hours; readies proposed public offering
Cassava Sciences (SAVA) -18.4% AH, commenced an underwritten public offering of shares; expects to grant underwriters a 30‐day option to purchase up to an additional 15% of shares.Offer size, terms and timing have
Seekingalpha · 11/12 21:57
Cassava Sciences Announces Proposed Public Offering of Common Stock
AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it is commencing an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. The Company expects to grant the underwriters a 30‐day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as sole book-running manager for the proposed offering.Cassava Sciences intends to use the net proceeds, if any, from the sale of the shares of common stock in the offering to fund a Phase 3 clinical program of sumifilam, the Company’s lead drug candidate, in patients with Alzheimer’s disease, for research and development for the Company’s product candidates and for general corporate purposes.The securities described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-237452) relating to the public offering of such securities, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 27, 2020 and declared effective by the SEC on May 5, 2020. The offering may be made only by a preliminary prospectus supplement and the accompanying prospectus. Before investing in the offering, you should read in their entirety the preliminary prospectus supplement, when available, and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in the preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering.A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at Copies of the preliminary prospectus supplement, when available, and the accompanying prospectus relating to these securities may also be obtained by sending a request to: Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022, or by email at press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.About Cassava Sciences, Inc.Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease.For More Information Contact:Eric Schoen, Chief Financial Officer Cassava Sciences, Inc. (512) 501-2450Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may include, without limitation, statements regarding (i) the terms of the proposed public offering, (ii) expected use of the proceeds of the proposed public offering and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii). Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, unfavorable market conditions, occurrence of force majeure, inability of one or more underwriters to participate in the proposed public offering, the Company’s inability to obtain adequate financing to fund its operations and necessary to develop or enhance its products, the Company’s ability to conduct or complete clinical studies on expected timelines, the Company’s ability to demonstrate the specificity, safety, efficacy or potential health benefits of its product candidates, the severity and duration of health care precautions given the COVID-19 pandemic and unanticipated impacts of the pandemic on the Company’s business operations. These and other factors are identified and described in more detail in the prospectus supplement to be filed with the SEC in connection with the proposed public offering, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the nine months ended September 30, 2020, which will be incorporated by reference in such preliminary prospectus supplement, and the other documents incorporated by reference in such preliminary prospectus supplement and Company’s other filings with the SEC. The Company does not undertake to update these forward-looking statements.
GlobeNewswire · 11/12 21:48
Cassava Sciences Q3 EPS $(0.06) Down From $(0.04) YoY
Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.06) per share. This is a 50 percent decrease over losses of $(0.04) per share from the same period last year.
Benzinga · 11/09 13:23
Mid-Afternoon Market Update: Dow Jumps 600 Points; Super Micro Computer Shares Climb On Upbeat Earnings
Toward the end of trading Wednesday, the Dow traded up 2.21% to 28,087.29 while the NASDAQ rose 3.83% to 11,588.19. The S&P also rose, gaining 2.67% to 3,459.28.
Benzinga · 11/04 19:43
BIIB, XPEV, CXW and PVAC among midday movers
Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repro Med Systems
Seekingalpha · 11/04 17:40
Biogen, Digirad leads healthcare gainers; Repro Med Systems, Aptevo Therapeutics among major losers
Gainers: Biogen (BIIB) +43%, Digirad (DRAD) +28%, Supernus Pharmaceuticals (SUPN) +21%, Jupiter Wellness (JUPW) +3%, Cassava Sciences (SAVA) +13%.Losers: Repro Med Systems (KRMD) -28%, Aptevo Therapeutics (APVO) -13%, Allogene Therapeutics (ALLO) -13%, Tabula Rasa HealthCare (TRHC) -17%, Aurora Cannabis (ACB) -9%.
Seekingalpha · 11/04 16:01
Cassava Sciences' sumifilam shows significant benefit in Alzheimer’s disease
Cassava Sciences (SAVA) announces additional clinical data of a Phase 2b study with sumifilam in patients with Alzheimer’s disease.In a clinical study funded by the National Institutes of Health, sumifilam
Seekingalpha · 11/04 13:37
UPDATE: Cassava Sciences Says 'Alzheimer's Patients Treated with Sumifilam Showed a Statistically Significant (p<0.001) Treatment Benefit on HMGB1'
Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer's Disease Alzheimer's Patients Treated with Sumifilam Showed a Statistically Significant
Benzinga · 11/04 13:17
Cassava Sciences Announces Additional Clinical Data From A Phase 2b Study Of Sumifilam In Alzheimer's Disease
Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer's Disease Alzheimer's Patients Treated with Sumifilam Showed a Statistically Significant
Benzinga · 11/04 13:16
Webull provides a variety of real-time SAVA stock news. You can receive the latest news about Cassava Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About SAVA
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.